The Watchman left atrial appendage (LAA) closure device (Boston Scientific) is associated with low 1-year stroke rates, despite being used commercially in older, sicker patients than seen in pivotal ...
The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their 1,000th WATCHMAN device procedure, a minimally invasive solution for ...
Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro successfully implanted the first WATCHMAN FLX Pro Device on April 1. MCH ...
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...
Please provide your email address to receive an email when new articles are posted on . A next-generation LAA closure device gained FDA approval to reduce risk for stroke in patients non-valvular AF.
TipRanks on MSN
Boston Scientific’s WATCHMAN FLX Pro registry: A new frontier in atrial fibrillation treatment
Boston Scientific (BSX) announced an update on their ongoing clinical study.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools ...
(Updated) SAN FRANCISCO, California — Preliminary data from the PREVAIL study of the Watchman (AtriTech/Boston Scientific) device for the prevention of stroke and systemic embolism in patients with ...
The WATCHMAN FLX Pro team (pictured here) has successfully completed 159 WATCHMAN procedures, and will now only use the updated WATCHMAN FLX Pro Device moving forward. (Courtesy Photo) Medical Center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback